6 Molecular testing turn around time in NSCLC before and after NGS commissioning in Milton Keynes University Hospital- An Audit 2022 –2023
Lung cancer is most common malignancy, with non-small cell lung cancer (NSCLC) the predominant subtype. Lung cancer accounts for more than 18% cancer related deaths (1). We aim to reflect on our practice of molecular testing on NSCLC, along with PD-L1 expression in 2022 –2023 (before and after NGS commissioning) which will define the choice of treatment, based on the expression of this ligand (immunotherapy alone vs chemotherapy plus immunotherapy).
Source: Lung Cancer - Category: Cancer & Oncology Authors: Faiza Saleem, Hany Eldeeb, Moyna Dawyer, Syed Azhar Javed Rizvi Tags: Basic Science Source Type: research
More News: Cancer | Cancer & Oncology | Chemotherapy | Hospitals | Immunotherapy | Lung Cancer | Non-Small Cell Lung Cancer | Science